论文部分内容阅读
[目的]评价长期输注人血白蛋白治疗肝硬化腹水的有效性、安全性,为临床选择治疗方案提供参考.[方法]计算机检索Medline、Embase、Cochrane Library、Pubmed、中国生物医学文献数据库、万方数据库、维普数据库、中国期刊全文数据库等.检索截止日期2018年5月.收集长期输注人血白蛋白联合利尿剂(试验组)与单独利尿剂(对照组)治疗肝硬化腹水患者的随机对照试验.由两名评价员独立纳入研究,提取资料,评价偏倚风险,采用RevMan5.2软件进行Meta分析.[结果]共纳入5篇文献803例患者,Meta分析结果显示:与对照组相比,试验组可以提高总生存率[HR=0.60,95％CI(0.44,0.83), P =0.002],显著降低并发症发生率[RR = 0.35, 95％CI(0,18,0.69),P =0.002],减少再次入院率[RR=0.23,95％CI(0.13,0.43),P <0.001]及腹水再发率[RR=0.17,95％CI(0.07,0.42),P 0.05).[结论]对于需要长期管理腹水的肝硬化患者,长期输注人血白蛋白可以提高总体生存率,减少并发症的发生率及再入院次数,且不增加不良反应发生率.“,”[Objective]The clinical efficacy and safety of human serum albumin for patients with cirrhosis and ascites were systematically assessed.[Methods]We searched Medline, Embase, Cochrane Library, Pubmed, China Biomedical Literature (CBM), WanFang Datebase, VIP and Chinese Journal Full-text database (CNKI). The search deadline from above databases was May 2018. A randomized controlled trial of long-term infusion of human albumin combined with diuretics(the experimental group) and separate diuretics (the control group) in patients with cirrhosis and ascites was performed. Two reviewers were independently involved in the studies using RevMan5.2 software, performed quality assessment, extracted the data,evaluated the risk of bias, and made the conclusions.[Results]A total of 803 patients with 5 articles were included. Meta-analysis showed that the overall survival rate was improved in the experimental group compared with the control group [HR=0.60,95％CI(0.44,0.83),P =0.002]. Data also showed the experimental group significantly reduced the incidence of complications [RR=0.35,95％CI(0.18,0.69) , P =0.002], re-admission rate [RR=0.23 ,95％CI(0.13,0.43),P <0.001] and ascites recurrence rate [RR=0.17,95％CI(0.07,0.42),P <0.001]. There were no significant differences between the two groups in the incidence of serious adverse reactions and human serum albumin related adverse events.[Conclusion]Long-term infusion of human serum albumin for patients with cirrhosis and ascites can increase the overall survival and reduce the incidence of complications and re-admissions. It does not increase the incidence of adverse reactions.